摘要
目的系统评价乌鸡白凤丸联合抗病毒治疗对慢性病毒性肝炎(慢性肝炎)和肝硬化的临床疗效和安全性。方法计算机检索中国知网(CNKI)、万方数据库(Wanfang Data)、维普(VIP)、中国生物医学文献服务系统(SinoMed)、PubMed、Embase、Cochrane Library 7个中英文数据库,检索的文献类型为乌鸡白凤丸治疗慢性肝炎和肝硬化的随机对照试验,检索时间为数据库建立到2021年3月1日。由专业人员进行双检索、双提取和双评价,使用RevMan 5.3软件进行Meta分析。结果最终纳入10篇文献,涉及867例患者。Meta分析结果显示,与单用抗病毒药物比较,乌鸡白凤丸联合抗病毒药物在改善临床总有效率[RR=1.32,95%CI(1.15,1.51),P<0.0001]、白蛋白[MD=2.88,95%CI(0.80,4.97),P=0.007]、丙氨酸氨基转移酶[MD=-28.49,95%CI(-46.15,-10.83),P=0.002]、天冬氨酸氨基转移酶[MD=-32.04,95%CI(-49.40,-14.67),P=0.0003]、总胆红素[MD=-19.10,95%CI(-27.37,-10.84),P<0.00001]、透明质酸[MD=-49.67,95%CI(-76.59,-22.75),P=0.0003]、层黏连蛋白[MD=-36.16,95%CI(-56.32,-16.00),P=0.0004]、血清Ⅲ型前胶原[MD=-24.25,95%CI(-48.43,-0.06),P=0.05]和Ⅳ型胶原[MD=-21.06,95%CI(-37.98,-4.14),P=0.01]方面差异显著,均具有统计学意义。安全性方面较好,但还需要进一步研究佐证。结论乌鸡白凤丸联合抗病毒治疗可以有效改善慢性肝炎和肝硬化的临床疗效,还需要开展大量高质量临床研究进一步验证。
Objective To systematically evaluate the clinical efficacy and safety of Wuji Baifeng Pills(乌鸡白凤丸) combined with antiviral treatment for chronic hepatitis and liver cirrhosis.Methods Seven Chinese and English databases,including China National Knowledge Infrastructure(CNKI),Wanfang Data,VIP,SinoMed,PubMed,Embase and Cochrane Library,were searched by computer.The type of literature searched was the randomized controlled trial of Wuji Baifeng Pills in the treatment of chronic hepatitis and liver cirrhosis.The retrieval time was from the establishment of the database to March 1,2021.Double retrieval,double extraction and double evaluation were carried out by professionals,and RevMan 5.3 software was used for Meta-analysis.Results A total of 10studies were included with 867 patients.The results of Meta-analysis showed that compared with antiviral drugs alone,Wuji Baifeng Pills combined with antiviral drugs could significantly improve the clinical response rate [RR = 1.32,95%CI(1.15,1.51),P < 0.000 1],albumin [MD = 2.88,95%CI(0.80,4.97),P = 0.007],alanine aminotransferase [MD =-28.49,95%CI(-46.15,-10.83),P = 0.002],aspartate aminotransferase [MD =-32.04,95%CI(-49.40,-14.67),P = 0.000 3],total bilirubin [MD =-19.10,95%CI(-27.37,-10.84),P < 0.000 01],hyaluronic acid [MD =-49.67,95%CI(-76.59,-22.75),P = 0.000 3],laminin [MD =-36.16,95%CI(-56.32,-16.00),P = 0.000 4],procollagen-Ⅲ-peptide [MD =-24.25,95%CI(-48.43,-0.06),P = 0.05],and collage type IV [MD =-21.06,95%CI(-37.98,-4.14),P = 0.01],with statistical differences.Better safety,but further research was needed to confirm.Conclusion Wuji Baifeng Pills combined with antiviral therapy could effectively improve the clinical efficacy of chronic hepatitis and liver cirrhosis,which needs to be further verified by a large number of high-quality studies.
作者
周鸿
江永萍
陈哲
强晓钰
彭莹莹
王辉
ZHOU Hong;JIANG Yong-ping;CHEN Zhe;QIANG Xiao-yu;PENG Ying-ying;WANG Hui(The Sixth Traditional Chinese Medicine Factory,Tianjin Pharmaceutical Da Ren Tang Group Corporation Ltd.,Tianjin 300401,China;Tianjin Pharmaceutical Da Ren Tang Group Corporation Ltd.,Tianjin 300193,China;Lerentang Pharmaceutical Factory,Tianjin Pharmaceutical Da Ren Tang Group Corporation Ltd.,Tianjin 300380,China;Evidence-based Medicine Center,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300382,China;National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin 300382,China)
出处
《中草药》
CAS
CSCD
北大核心
2022年第23期7491-7498,共8页
Chinese Traditional and Herbal Drugs
基金
天津市青年拔尖人才计划项目(125Z15XSGC31)
津教委“十三五”创新团队培养计划-中药临床评价方法(TD13-5047)。
关键词
乌鸡白凤丸
慢性病毒性肝炎
肝硬化
随机对照试验
抗病毒
Wuji Baifeng Pills
chronic virus hepatitis
liver cirrhosis
randomized controlled trial
antiviral
